Responder of Gefitinib Plus Crizotinib in Osimertinib Failure EGFR-mutant NSCLC-Resistant With Newly Identified STRN-ALK by Next-Generation Sequencing
Author:
Publisher
Elsevier BV
Subject
Pulmonary and Respiratory Medicine,Oncology
Reference5 articles.
1. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation–positive non–small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study;Zhou;Lancet Oncol,2011
2. Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study phase II extension component;Yang;J Clin Oncol,2017
3. A Rare STRN-ALK fusion in lung adenocarcinoma identified using next-generation sequencing-based circulating tumor DNA profiling exhibits excellent response to crizotinib;Yang;Mayo Clin Proc Innov Qual Outcomes,2017
4. Case report of non–small cell lung cancer with STRN-ALK translocation: a nonresponder to alectinib;Nakanishi;J Thorac Oncol,2017
5. Identification and development of a lung adenocarcinoma PDX model with STRN-ALK fusion;Ren;Clin Lung Cancer,2018
Cited by 20 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Case Report: A rare case of non-small cell lung cancer with STRN-ALK fusion in a patient in very poor condition treated with first-line ensartinib;Frontiers in Oncology;2023-09-22
2. Dynamics of disease progression during treatment with Osimertinib in patients with EGFR T790M‐positive non‐small cell lung cancer;Cancer Medicine;2023-04-25
3. Therapeutic Advances of Rare ALK Fusions in Non-Small Cell Lung Cancer;Current Oncology;2022-10-16
4. STRN-ALK Fusion in Lung Adenocarcinoma with Brain Metastasis Responded Well to Ensartinib: A Case Report;Current Oncology;2022-09-21
5. Lung adenocarcinoma with EGFR 19Del and an ALK rearrangement benefits from alectinib instead of an EGFR-TKI: A case report;Medicine;2022-09-02
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3